Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 7,767 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo; placebo comparator condition Clear all
Completed Phase 2 Interventional Results available

Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach

NCT02419313
View directory record Official record
Conditions
Parkinson, Tremor
Interventions
incobotulinumtoxinA, Saline
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 2 Interventional Results available

Omega-3 for Depression and Other Cardiac Risk Factors - 2

NCT02021669
View directory record Official record
Conditions
Depression
Interventions
Omega-3 supplement, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 14, 2026, 9:40 PM EDT
Completed No phase listed Observational

A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa

NCT01140841
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Fipamezole ODT, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Torrance, California • Bingham Farms, Michigan • Willingboro, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

NCT05142722
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
Placebo, Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
2,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Nicotinamide to Treat Alzheimer's Disease

NCT00580931
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Nicotinamide, Enduramide placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
50 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

NCT06546995
View directory record Official record
Conditions
Alzheimer's Disease, Healthy Elderly
Interventions
NMRA-323511, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
26
States / cities
Chandler, Arizona • Tempe, Arizona • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 14, 2026, 9:40 PM EDT
Recruiting Phase 3 Interventional

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
15,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
357
States / cities
Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 284 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART

NCT00270205
View directory record Official record
Conditions
HIV Infections
Interventions
LC002 standard vaccination, LC002 high-dose vaccination, LC002 placebo vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
5
States / cities
Sacramento, California • Chicago, Illinois • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 2 Interventional Results available

Abatacept as GVHD Prophylaxis Phase 2

NCT01743131
View directory record Official record
Conditions
Graft vs Host Disease, Malignancy
Interventions
Abatacept, placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Oakland, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 2 Interventional

Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects

NCT03717272
View directory record Official record
Conditions
Marijuana Abuse
Interventions
AEF0117, Placebo oral capsule
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
21 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available

Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer

NCT01352637
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
DCS (D-Cycloserine ) + Prolonged Imaginal Exposure, DCS (D-Cycloserine ) + Virtual Reality Exposure, Placebo + Prolonged Imaginal Exposure, Placebo (sugar pill) + Virtual Reality Exposure
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
5
States / cities
Long Beach, California • Los Angeles, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

NCT01474330
View directory record Official record
Conditions
Healthy
Interventions
Pomalidomide, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 2 Interventional Results available

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01350128
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT001 MDI, Ipratropium Bromide HFA Inhalation Aerosol, Placebo MDI
Drug · Other
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Panama City, Florida • Winter Park, Florida • Cherry Hill, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

NCT01572792
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
179
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 146 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 4 Interventional

Patent Foramen Ovale in Cryptogenic Stroke Study

NCT00697151
View directory record Official record
Conditions
Ischemic Stroke, Patent Foramen Ovale
Interventions
Warfarin, Aspirin
Drug
Lead sponsor
Columbia University
Other
Eligibility
30 Years to 85 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Fish Oil Brain Delivery Study

NCT02541929
View directory record Official record
Conditions
Brain Health
Interventions
Docosahexaenoic acid
Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
55 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00613002
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
60
States / cities
Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

NCT00477672
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103), Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Gilbert, Arizona • Phoenix, Arizona • Berkeley, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 2 Interventional Results available

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

NCT04328077
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-101, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
31
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects

NCT02876796
View directory record Official record
Conditions
PD Effects of GS-0976 (NDI-010976) on Fractional DNL
Interventions
GS-0976, Placebo, 1-13C acetate, Fructose solution
Drug · Other
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Oct 14, 2026, 9:40 PM EDT
Terminated Not applicable Interventional Results available

Topiramate for Alcohol Use in Posttraumatic Stress Disorder

NCT01408641
View directory record Official record
Conditions
Alcohol Dependence, Alcoholism, Alcohol Abuse, Alcohol Use Disorder, PTSD, Posttraumatic Stress Disorder
Interventions
Topiramate, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 64 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Gabapentin for Pain Management During Dilation and Evacuation

NCT03635905
View directory record Official record
Conditions
Pain
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

NCT01844505
View directory record Official record
Conditions
Unresectable or Metastatic Melanoma
Interventions
Nivolumab, Ipilimumab, Placebo for Nivolumab, Placebo for Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
46
States / cities
Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 14, 2026, 9:40 PM EDT
Completed Phase 2 Interventional

Dose-Response Study of Iocide Oral Rinse

NCT01103102
View directory record Official record
Conditions
Gingivitis
Interventions
Iocide Oral Rinse, Placebo
Drug
Lead sponsor
Biomedical Development Corporation
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 14, 2026, 9:40 PM EDT